Profound Medical (NASDAQ:PROF - Get Free Report) shares were down 1.6% during trading on Friday . The stock traded as low as $6.82 and last traded at $6.85. 18,183 shares were traded during trading, a decline of 85% from the average daily volume of 117,764 shares. The stock had previously closed at $6.96.
Analyst Upgrades and Downgrades
Several research firms have commented on PROF. Raymond James Financial raised shares of Profound Medical from an "outperform" rating to a "strong-buy" rating and set a $11.00 target price on the stock in a report on Monday, July 27th. Weiss Ratings cut Profound Medical from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $11.50.
Get Our Latest Research Report on PROF
Profound Medical Stock Performance
The business has a 50 day moving average price of $7.04 and a 200-day moving average price of $6.74. The company has a market capitalization of $248.93 million, a price-to-earnings ratio of -6.99 and a beta of 0.73.
Profound Medical (NASDAQ:PROF - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.04). The business had revenue of $2.48 million for the quarter, compared to the consensus estimate of $4.75 million. Profound Medical had a negative return on equity of 63.03% and a negative net margin of 171.57%. As a group, equities analysts predict that Profound Medical will post -0.81 EPS for the current fiscal year.
Hedge Funds Weigh In On Profound Medical
Large investors have recently modified their holdings of the company. Royal Bank of Canada lifted its position in Profound Medical by 3.5% in the 1st quarter. Royal Bank of Canada now owns 435,997 shares of the company's stock valued at $2,537,000 after acquiring an additional 14,795 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of Profound Medical by 5.5% during the 2nd quarter. Raymond James Financial Inc. now owns 941,879 shares of the company's stock valued at $5,557,000 after acquiring an additional 49,000 shares during the period. Bank of America Corp DE grew its holdings in Profound Medical by 14.3% during the third quarter. Bank of America Corp DE now owns 200,160 shares of the company's stock valued at $979,000 after purchasing an additional 24,974 shares during the period. National Bank of Canada FI grew its stake in shares of Profound Medical by 7.3% during the 3rd quarter. National Bank of Canada FI now owns 172,883 shares of the company's stock worth $845,000 after acquiring an additional 11,704 shares during the period. Finally, CM Management LLC bought a new position in Profound Medical during the fourth quarter worth about $630,000. 47.86% of the stock is currently owned by institutional investors.
About Profound Medical
(
Get Free Report)
Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company's proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.
The company's lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
